{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:50:53Z","timestamp":1788364253618,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T00:00:00Z","timestamp":1609632000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T00:00:00Z","timestamp":1609632000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s00280-020-04203-z","type":"journal-article","created":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T09:02:59Z","timestamp":1609664579000},"page":"289-294","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Pegylated liposomal doxorubicin-induced renal toxicity in retroperitoneal liposarcoma: a case report and literature review"],"prefix":"10.1007","volume":"87","author":[{"given":"Malvi","family":"Savani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katti","family":"Woerner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Birkenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0690-9595","authenticated-orcid":false,"given":"Keith M.","family":"Skubitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,3]]},"reference":[{"issue":"6 Suppl 13","key":"4203_CR1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1053\/j.seminoncol.2004.08.010","volume":"31","author":"DS Alberts","year":"2004","unstructured":"Alberts DS et al (2004) Efficacy and safety of liposomal anthracyclines in phase I\/II clinical trials. Semin Oncol 31(6 Suppl 13):53\u201390","journal-title":"Semin Oncol"},{"issue":"4","key":"4203_CR2","first-page":"987","volume":"54","author":"A Gabizon","year":"1994","unstructured":"Gabizon A et al (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54(4):987\u2013992","journal-title":"Cancer Res"},{"issue":"1","key":"4203_CR3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/j.1552-4604.1996.tb04152.x","volume":"36","author":"DW Northfelt","year":"1996","unstructured":"Northfelt DW et al (1996) Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi\u2019s sarcoma. J Clin Pharmacol 36(1):55\u201363","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"4203_CR4","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s00280-017-3420-8","volume":"80","author":"KM Skubitz","year":"2017","unstructured":"Skubitz KM et al (2017) Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value. Cancer Chemother Pharmacol 80(4):787\u2013798","journal-title":"Cancer Chemother Pharmacol"},{"key":"4203_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13569-018-0111-0","volume":"9","author":"M Savani","year":"2019","unstructured":"Savani M, Murugan P, Skubitz KM (2019) Long-term cure of soft tissue sarcoma with pegylated-liposomal doxorubicin after doxorubicin and ifosfamide failure. Clin Sarcoma Res 9:1","journal-title":"Clin Sarcoma Res"},{"issue":"1","key":"4203_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/00001813-199801000-00005","volume":"9","author":"KM Skubitz","year":"1998","unstructured":"Skubitz KM, Skubitz AP (1998) Mechanism of transient dyspnea induced by pegylated-liposomal doxorubicin (Doxil). Anticancer Drugs 9(1):45\u201350","journal-title":"Anticancer Drugs"},{"issue":"12","key":"4203_CR7","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1634\/theoncologist.2011-0216","volume":"17","author":"TL Cannon","year":"2012","unstructured":"Cannon TL et al (2012) Squamous cell carcinoma of the oral cavity in nonsmoking women: a new and unusual complication of chemotherapy for recurrent ovarian cancer? Oncologist 17(12):1541\u20131546","journal-title":"Oncologist"},{"issue":"12","key":"4203_CR8","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1634\/theoncologist.2012-0358","volume":"17","author":"K Matsuo","year":"2012","unstructured":"Matsuo K et al (2012) Long-term pegylated liposomal doxorubicin use and oromaxillary squamous cell carcinoma in endometrial cancer. Oncologist 17(12):1598\u20131599","journal-title":"Oncologist"},{"issue":"1","key":"4203_CR9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s00280-019-03849-8","volume":"84","author":"DF Pease","year":"2019","unstructured":"Pease DF et al (2019) Development of cutaneous squamous cell carcinoma after prolonged exposure to pegylated liposomal doxorubicin and hand-foot syndrome: a newly recognized toxicity. Cancer Chemother Pharmacol 84(1):217\u2013221","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"4203_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00280-019-03909-z","volume":"85","author":"L Meng","year":"2020","unstructured":"Meng L et al (2020) Incidence of interstitial pneumonitis in breast cancer patients treated with pegylated liposomal doxorubicin. Cancer Chemother Pharmacol 85(1):3\u20137","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"4203_CR11","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/hdi.12196","volume":"18","author":"PL Carron","year":"2014","unstructured":"Carron PL, Padilla M, Maurizi Balzan J (2014) Nephrotic syndrome and acute renal failure during pegylated liposomal doxorubicin treatment. Hemodial Int 18(4):846\u2013847","journal-title":"Hemodial Int"},{"issue":"12","key":"4203_CR12","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1634\/theoncologist.2011-0422","volume":"17","author":"M Kwa","year":"2012","unstructured":"Kwa M et al (2012) Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences? Oncologist 17(12):1534\u20131540","journal-title":"Oncologist"},{"issue":"7","key":"4203_CR13","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1177\/1078155218798157","volume":"25","author":"KE Yemm","year":"2019","unstructured":"Yemm KE et al (2019) Renal toxicity with liposomal doxorubicin in metastatic breast cancer. J Oncol Pharm Pract 25(7):1738\u20131742","journal-title":"J Oncol Pharm Pract"},{"issue":"2","key":"4203_CR14","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30(2):239\u2013245","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"4203_CR15","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/ki.2012.484","volume":"84","author":"KD Jhaveri","year":"2013","unstructured":"Jhaveri KD et al (2013) Glomerular diseases seen with cancer and chemotherapy: a narrative review. Kidney Int 84(1):34\u201344","journal-title":"Kidney Int"},{"issue":"5","key":"4203_CR16","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1053\/j.ajkd.2012.08.048","volume":"61","author":"N Mohamed","year":"2013","unstructured":"Mohamed N et al (2013) Collapsing glomerulopathy following anthracycline therapy. Am J Kidney Dis 61(5):778\u2013781","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"4203_CR17","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1681\/ASN.2007101109","volume":"19","author":"J Guo","year":"2008","unstructured":"Guo J et al (2008) RAGE mediates podocyte injury in adriamycin-induced glomerulosclerosis. J Am Soc Nephrol 19(5):961\u2013972","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"4203_CR18","first-page":"459","volume":"77","author":"A Gabizon","year":"1986","unstructured":"Gabizon A, Meshorer A, Barenholz Y (1986) Comparative long-term study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration. J Natl Cancer Inst 77(2):459\u2013469","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"4203_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1081\/LPR-120017484","volume":"13","author":"A Gabizon","year":"2003","unstructured":"Gabizon A (2003) Emerging role of liposomal drug carrier systems in cancer chemotherapy. J Liposome Res 13(1):17\u201320","journal-title":"J Liposome Res"},{"issue":"1","key":"4203_CR20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00280-011-1664-2","volume":"69","author":"NM La-Beck","year":"2012","unstructured":"La-Beck NM et al (2012) Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients. Cancer Chemother Pharmacol 69(1):43\u201350","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"4203_CR21","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.ygyno.2007.04.011","volume":"106","author":"Y Li","year":"2007","unstructured":"Li Y et al (2007) Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction. Gynecol Oncol 106(2):375\u2013380","journal-title":"Gynecol Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-020-04203-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-020-04203-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-020-04203-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T21:29:46Z","timestamp":1612906186000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-020-04203-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,3]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["4203"],"URL":"https:\/\/doi.org\/10.1007\/s00280-020-04203-z","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,3]]},"assertion":[{"value":"28 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflicts of interest in preparing this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable, although consent to publish was obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}